Physician profile
Danny Shearer
NPI 1275594905
$10,847.66
in general payments reported to CMS, 2019-2025
29 companies · $3,587 in 2025
The $3,587 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $485 · 2021: $1,235 · 2022: $1,804 · 2023: $1,785 · 2024: $1,383 · 2025: $3,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Long Term Medical Supply Or Device Loan: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,685.03 |
| Long Term Medical Supply Or Device Loan | $2,069.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $2,069.44 | 2025 | Pentax Medical |
| Abbvie INC. | $2,017.88 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $1,583.53 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,456.65 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Ardelyx, INC. | $576.74 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $515.16 | 2019-2024 | Linzess |
| Celgene Corporation | $395.13 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $332.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.77 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $239.24 | 2021-2025 | Sucraid |
| Gilead Sciences, INC. | $227.59 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $187.47 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $155.49 | 2019-2023 | Clenpiq |
| Echosens North America, INC. | $117.00 | 2023 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $106.70 | 2023-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $98.17 | 2021-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $71.01 | 2025 | Iqirvo |
| Pfizer INC. | $69.47 | 2025 | |
| Madrigal Pharmaceuticals | $60.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Ucb, INC. | $46.48 | 2019 | |
| Evoke Pharma, INC. | $45.78 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.80 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $35.95 | 2025 | Zenpep |
| Celltrion USA INC. | $29.72 | 2025 | Vegzelma |
| Allergan, INC. | $15.97 | 2019 | |
| W. L. Gore & Associates, INC. | $15.01 | 2023 | Gore Cardioform Septal Occluder |
| Novo Nordisk INC | $14.60 | 2025 | Wegovy |
| Genzyme Corporation | $13.71 | 2022 | |
| Olympus America INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Shearer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.